Agios Pharmaceuticals (AGIO) Return on Sales (2012 - 2026)

Agios Pharmaceuticals has reported Return on Sales for 15 years, with the latest figure at 0.05% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 6.0% year-over-year to 0.05%; the trailing twelve-month figure through Mar 2026 stood at 0.06% (down 24.0% YoY), and the FY2025 full-year result was 0.08%, down 26.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.05%, up from 0.05% in the prior quarter.
• The five-year high for Return on Sales was 1.06% in Q3 2024, with the low at 0.15% in Q1 2023.
• Historically, Return on Sales has averaged 0.01% across 5 years, with a median of 0.09% in 2024.
• Annual changes were most pronounced in 2024 — Return on Sales soared 118 bps — and 2025, when it sank 114 bps.
• Agios Pharmaceuticals' Return on Sales stood at 0.0% in 2022, then tumbled by 3490 bps to 0.14% in 2023, then jumped by 33 bps to 0.09% in 2024, then surged by 40 bps to 0.05% in 2025, then climbed by 12 bps to 0.05% in 2026.
• The last three Return on Sales figures came in at 0.05% (Q1 2026), 0.05% (Q4 2025), and 0.08% (Q3 2025), per Business Quant data.